KR20230153411A - 치료 목적을 위한 새로운 바이러스 입자 - Google Patents
치료 목적을 위한 새로운 바이러스 입자 Download PDFInfo
- Publication number
- KR20230153411A KR20230153411A KR1020237032657A KR20237032657A KR20230153411A KR 20230153411 A KR20230153411 A KR 20230153411A KR 1020237032657 A KR1020237032657 A KR 1020237032657A KR 20237032657 A KR20237032657 A KR 20237032657A KR 20230153411 A KR20230153411 A KR 20230153411A
- Authority
- KR
- South Korea
- Prior art keywords
- leu
- ser
- lys
- glu
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159746 | 2021-02-26 | ||
| EP21159746.3 | 2021-02-26 | ||
| PCT/EP2022/054766 WO2022180203A1 (en) | 2021-02-26 | 2022-02-25 | New virus particles for therapeutic purposes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230153411A true KR20230153411A (ko) | 2023-11-06 |
Family
ID=74844711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237032657A Pending KR20230153411A (ko) | 2021-02-26 | 2022-02-25 | 치료 목적을 위한 새로운 바이러스 입자 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4297763A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024508823A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230153411A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117241812A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022226407A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3208055A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2023002508A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305349A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009650A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022180203A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL326615A (en) | 2023-08-31 | 2026-04-01 | Abalos Therapeutics Gmbh | Virus particles with improved entry into tumor cells |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| EP3373959B1 (en) * | 2015-11-12 | 2022-06-29 | Hookipa Biotech GmbH | Arenavirus particles as cancer vaccines |
| DE102018215551A1 (de) * | 2018-09-12 | 2020-03-12 | Virolutions Biotech Gmbh | Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten |
-
2022
- 2022-02-25 WO PCT/EP2022/054766 patent/WO2022180203A1/en not_active Ceased
- 2022-02-25 KR KR1020237032657A patent/KR20230153411A/ko active Pending
- 2022-02-25 CN CN202280030958.8A patent/CN117241812A/zh active Pending
- 2022-02-25 JP JP2023551984A patent/JP2024508823A/ja active Pending
- 2022-02-25 CA CA3208055A patent/CA3208055A1/en active Pending
- 2022-02-25 EP EP22711182.0A patent/EP4297763A1/en active Pending
- 2022-02-25 IL IL305349A patent/IL305349A/en unknown
- 2022-02-25 AU AU2022226407A patent/AU2022226407A1/en active Pending
- 2022-02-25 MX MX2023009650A patent/MX2023009650A/es unknown
-
2023
- 2023-08-24 CL CL2023002508A patent/CL2023002508A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022226407A1 (en) | 2023-09-28 |
| IL305349A (en) | 2023-10-01 |
| EP4297763A1 (en) | 2024-01-03 |
| CA3208055A1 (en) | 2022-09-01 |
| WO2022180203A1 (en) | 2022-09-01 |
| AU2022226407A9 (en) | 2024-01-25 |
| JP2024508823A (ja) | 2024-02-28 |
| US20220273741A1 (en) | 2022-09-01 |
| CL2023002508A1 (es) | 2024-01-26 |
| CN117241812A (zh) | 2023-12-15 |
| MX2023009650A (es) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7114532B2 (ja) | 増強された養子細胞療法 | |
| CN110393791B (zh) | hnRNPA2B1的抗感染作用及其应用 | |
| JP2005537802A (ja) | ラブドウイルスの組み換え型変異体及びその使用方法 | |
| WO2003005964A2 (en) | Recombinant vsv for the treatment of tumor cells | |
| CN108307642B (zh) | 改造的白介素12及其在制备治疗肿瘤药物中的用途 | |
| CN110420331B (zh) | Alkbh5抑制物在治疗病毒感染性疾病中的应用 | |
| JP2020503390A (ja) | 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法 | |
| JP2021519747A (ja) | 腫瘍を治療するための仮性狂犬病ウイルス | |
| JP5846650B2 (ja) | ベクター産生型腫瘍標的細胞 | |
| CN117241812A (zh) | 用于治疗目的新病毒颗粒 | |
| CN110636853B (zh) | 重组溶瘤病毒 | |
| HU227667B1 (en) | Novel expression vectors and uses thereof | |
| WO2023205661A2 (en) | Compositions and methods for viral vectors | |
| TW202317172A (zh) | Tnfsf-l融合蛋白及其用途 | |
| JP7227654B2 (ja) | 固形癌及び微生物感染を治療するための方法及び組成物 | |
| JP2003509472A (ja) | M3ポリペプチドの治療的使用 | |
| US20210009963A1 (en) | Oncolytic t7 bacteriophage having cytokine gene and displaying homing peptide on capsid and its use for treating cancer | |
| CN120924501B (zh) | 双基因工程化的间充质干细胞及其应用 | |
| JP2022541030A (ja) | hnRNPA2B1の抗感染作用及びその応用 | |
| JP2024525781A (ja) | 腫瘍溶解性ウイルス及びその使用 | |
| AU2008201293B2 (en) | Recombinant VSV for the treatment of tumor cells | |
| CN121780453A (zh) | 一种高度肿瘤特异性和高效杀伤工程病毒的制备与应用 | |
| KR20230095460A (ko) | 흑색종 치료를 위한 sFlt-1을 과발현하는 중간엽줄기세포 및 이의 용도 | |
| CN118773145A (zh) | 一种表达i型干扰素和pkr干扰rna的重组hsv-1溶瘤病毒及其构建方法和应用 | |
| HK40017244A (en) | Recombinant oncolytic virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |